Effect of isotretinoin on endogenous tissue-type plasminogen activator (t-PA) and plasminogen activator inhibitor 1 (PAI-1) in humans.
The effect of isotretinoin on fibrinolysis was investigated in 10 healthy, male volunteers in a randomized, double-blind, crossover-designed study. Isotretinoin (40 mg) was administered in the morning and in the evening for 5 days. t-PA, u-PA and PAI-1 antigen and activity in plasma were measured every morning at 9 a.m. on days 1 to 4 and every 3 hours over 24 hours on day 5. Isotretinoin treatment had no significant stimulatory effect on endogenous t-PA antigen and activity in morning plasma samples nor on their circadian variation. Also, u-PA antigen levels did not change after isotretinoin treatment. Mean PAI-1 antigen and PAI activity in 9 a.m. plasma samples were non-significantly higher during isotretinoin than during placebo treatment. After treatment with isotretinoin a significant rise of fasting triglyceride plasma levels was observed as compared to placebo. The study shows that isotretinoin has no clinically significant effect on endogenous fibrinolysis.
Wallnöfer
A E
AE
Centre for Human Drug Research, University Hospital Leiden, The Netherlands.
van Griensven
J M
JM
Schoemaker
H C
HC
Cohen
A F
AF
Lambert
W
W
Kluft
C
C
Meijer
P
P
Kooistra
T
T
D000328:Adult; D000941:Antigens / Q000097:blood; D004311:Double-Blind Method; D006801:Humans; D015474:Isotretinoin / Q000494:pharmacology*; D008297:Male; D017395:Plasminogen Activator Inhibitor 1 / Q000097:blood* / Q000276:immunology; D012016:Reference Values; D010959:Tissue Plasminogen Activator / Q000187:drug effects* / Q000276:immunology; D014568:Urokinase-Type Plasminogen Activator / Q000276:immunology
D000941:Antigens; D017395:Plasminogen Activator Inhibitor 1; D010959:Tissue Plasminogen Activator; D014568:Urokinase-Type Plasminogen Activator; D015474:Isotretinoin